Sight Sciences, Inc., (SGHT): Price and Financial Metrics
GET POWR RATINGS... FREE!
SGHT Stock Price Chart Interactive Chart >
SGHT Price/Volume Stats
|Current price||$9.16||52-week high||$42.57|
|Prev. close||$9.21||52-week low||$6.25|
|Day high||$9.29||Avg. volume||327,429|
|50-day MA||$8.39||Dividend yield||N/A|
|200-day MA||$16.12||Market Cap||435.92M|
Sight Sciences, Inc., (SGHT) Company Bio
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Most Popular Stories View All
SGHT Latest News Stream
|Loading, please wait...|
SGHT Latest Social Stream
View Full SGHT Social Stream
Latest SGHT News From Around the Web
Below are the latest news stories about Sight Sciences Inc that investors may wish to consider to help them evaluate SGHT as an investment opportunity.
MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced plans to participate in the upcoming Citi Virtual Healthcare Conference. Sight Sciences’ management is scheduled to participate in a fireside chat February 23, 2022, at 8:45am PT. Interested parties may access a live and archived webcast of the fireside
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.
Educational campaign aims to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucomaMENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise
Sight Sciences (SGHT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
SGHT Price Returns